Czech
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
15 Výsledek
Modulators for amyloid beta
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
PRIORITY TO RELATED APPLICATIONS(S)
This application claims the benefit of European Patent Application No. 08150173.6, filed Jan. 11, 2008, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most common cause of dementia in later
Modulators of amyloid beta
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most common cause of dementia in later life. Pathologically, AD is characterized by the deposition of amyloid in extracellular plaques and intracellular neurofibrillary tangles in the brain. The amyloid plaques are mainly composed of
Modulators for amyloid beta
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most common cause of dementia in later life. Pathologically, AD is characterized by the deposition of amyloid in extracellular plaques and intracellular neurofibrillary tangles in the brain. The amyloid plaques are mainly composed of
Bridged piperidine derivatives
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
PRIORITY TO RELATED APPLICATION(S)
This application claims the benefit of European Patent Application No 11156587.5, filed Mar. 2, 2011, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most common cause of dementia in later life.
Heteroaryl substituted piperidines
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
PRIORITY TO RELATED APPLICATION(S)
This application claims the benefit of European Patent Application No. 10153843.7, filed Feb. 17, 2010, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most common cause of dementia in later
Heterocyclic gamma secretase modulators
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
PRIORITY TO RELATED APPLICATION(S)
This application claims the benefit of European Patent Application No. 08168719.6, filed Nov. 10, 2008, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most common cause of dementia in later
5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF THE INVENTION
The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions
Anti-dementia drug
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
SUMMARY OF THE INVENTION
The present invention relates to an anti-dementia agent which comprises rolipram (4-[3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone) as an active ingredient.
As the proportion of aged people grows larger in the society, countermeasures against senile dementia causes by
Bridged piperidine derivatives
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
The present invention relates to compounds of formula
##STR00002## hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R.sup.1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, S-lower alkyl substituted by halogen or
Bicyclic heteroaryl derivatives
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a National Stage Entry of PCT Application No. PCT/EP2017/074927, filed on Oct. 2, 2017, which is incorporated herein by reference in its entirety, which claims benefit of priority to European Application No. 16192237.2, filed on Oct. 4,
Bridged piperidine derivatives
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
The present invention relates to a compound of formula
##STR00002## wherein HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R.sup.1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R.sup.2 is
Fused pyrimidine derivatives
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
SUMMARY
The present invention relates to compounds of formula I,
##STR00003## wherein R.sup.1 is phenyl, lower alkyl, C.sub.3-6-cycloalkyl, --CH.sub.2--C.sub.3-6-cycloalkyl, or bridged C.sub.3-5-cycloalkyl, optionally substituted by one, two or three substituents, selected from halogen, lower alkyl
Composition comprising starch or dietary fiber from gramineae plant for prevention and treatment of ischemic diseases and degenerative brain disease
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
This application is the U.S. National Phase under 35 U.S.C. .sctn.371 of International Application PCT/KR2008/003975, filed on Jul. 4, 2008, which claims priority to Korean Patent Application No. 10-2008-0064291, filed on Jul. 3, 2008 and Korean Patent Application No. 10-2007-0066887, filed on Jul.
Human G protein-coupled receptor and modulators thereof for the treatment of cell death-related disorders
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
FIELD OF THE INVENTION
The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is expressed endogenously by neuronal cells or muscle cells.
(4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND OF THE INVENTION
The present invention relates to (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamide derivatives, and to pharmaceutical compositions and methods of treatment.
The compounds of the present invention are inhibitors of zinc metalloendopeptidases, especially
Nejúplnější databáze léčivých bylin podložená vědou
- Funguje v 55 jazycích
- Bylinné léky podporované vědou
- Rozpoznávání bylin podle obrázku
- Interaktivní mapa GPS - označte byliny na místě (již brzy)
- Přečtěte si vědecké publikace související s vaším hledáním
- Hledejte léčivé byliny podle jejich účinků
- Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty
Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu
